

TIDOMET CR

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
Abbreviated Prescribing information for TIDOMET CR (levodopa 100/200 mg and carbidopa 25/50 mg Controlled Release Tablets) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Levodopa, the metabolic precursor of dopamine, converted to dopamine in the brain and act as antiparkinsonian agent. Carbidopa inhibits decarboxylation of peripheral levodopa. It does not cross the blood brain barrier; hence the administration of carbidopa with levodopa makes more levodopa available for transport to the brain. **INDICATION:** indicated in the treatment of the Parkinson's disease. **DOSAGE AND ADMINISTRATION:** Ratio of levodopa and carbidopa is 4:1 as either the 200-50 tablet or the 100-25 tablet. Most patients have been adequately treated with doses of levodopa and carbidopa, that provide 400 to 1600mg of levodopa per day, administered as divided doses at intervals ranging from 4 to 8 hours during the waking day. **CONTRAINDICATIONS:** Contraindicated with nonselective Monoamine Oxidase (MAO) inhibitors, patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma. **WARNINGS & PRECAUTIONS:** Neuroleptic malignant syndrome (NMS), central nervous system (CNS) effects, e.g., dyskinesias (involuntary movements), hyperpyrexia and confusion, impulse control/compulsive behaviors, hallucinations/psychotic-like behavior, depression and melanoma. Periodic evaluations of hepatic, hematopoietic, cardiovascular, and renal function are recommended. **DRUG INTERACTIONS:** Interacts with monoamine oxidase inhibitors, dopamine D₂ receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone), isoniazid, iron salts and metoclopramide. **ADVERSE REACTIONS:** Dyskinesia, nausea, hallucinations, confusion, dizziness, depression, urinary tract infection, headache, asthenia, fatigue, malignant melanoma and rash, abdominal pain, distress, chest pain, cardiac irregularities, hypertension, myocardial infarction, hypotension including orthostatic hypotension, palpitation, phlebitis, syncope, anorexia, bruxism, burning sensation of the tongue, constipation, dark saliva, development of duodenal ulcer, diarrhea, dry mouth, dyspepsia, dysphagia, flatulence, gastrointestinal bleeding, vomiting, leukopenia, thrombocytopenia, agranulocytosis, angioedema, urticaria, pruritus, Henoch-Schonlein purpura, edema, weight gain, weight loss, back pain, leg pain, muscle cramps, shoulder pain, psychotic episodes including delusions, hallucinations and paranoid ideation, upper respiratory infection, dyspnea, pharyngeal pain, cough, flushing, increased sweating, alopecia, dark sweat, diplopia, blurred vision, priapism, urinary frequency, urinary incontinence, urinary retention.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/TIDOMET CR/100,200,25,50mg/May-15/01/AbPI

(Additional information is available on request)